Special Survey for Paediatric Subjects
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 1Diabetes Mellitus, Type 2
- Interventions
- Registration Number
- NCT01487382
- Lead Sponsor
- Novo Nordisk A/S
- Brief Summary
This study is conducted in Japan. The aim of this study is to collect safety and efficacy data when using NovoRapid® (insulin aspart) in children with type 1 and type 2 diabetes under normal clinical practice conditions.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 241
Inclusion Criteria
- Requiring insulin therapy
- No treatment history of NovoRapid® (insulin aspart)
Exclusion Criteria
Not provided
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Insulin Aspart insulin aspart -
- Primary Outcome Measures
Name Time Method Hypoglycaemic events
- Secondary Outcome Measures
Name Time Method HbA1c (glycosylated haemoglobin) Physicial examination Adverse events
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What are the molecular mechanisms of insulin aspart in pediatric type 1 and type 2 diabetes management?
How does insulin aspart compare to other rapid-acting insulins in pediatric diabetes treatment outcomes?
Which biomarkers correlate with improved glycemic control using insulin aspart in children with diabetes?
What adverse events are associated with insulin aspart use in pediatric populations and how are they managed?
Are there combination therapies involving insulin aspart that enhance efficacy in pediatric diabetes compared to standard-of-care?